All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1600+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Kelun-Biotech's Tagitanlimab (PD-L1 inhibitor) lands Chinese NMPA approval for first-line treatment of metastatic nasopharyngeal cancer, in combo with cisplatin/gemcitabine
Monoclonal antibody, nasopharyngeal cancer - Read more

THE GOOD
Business Development

As part of Exicure’s acquisition of GPCR Therapeutics' US business unit, former also acquires clinical-stage blood cancer asset burixafor (CXCR4 inhibitor)
Small molecule, myeloma, lymphoma, cancer - Read more

THE GOOD
Clinical Trials

Valneva touts positive Ph2 data for their Ixchiq vaccine in children against chikungunya virus
Vaccine, chikungunya virus infection - Read more

Vigil Neuroscience's showcases “promising” Ph1 results for VG-3927 (TREM2 agonist) in Alzheimer's disease
Small molecule, Alzheimer’s disease - Read more

Aro Biotherapeutics begins Ph1b trial of ABX1100 (targeting Gys1 gene) for late-onset Pompe disease treatment
Protein-siRNA conjugate, Pompe disease - Read more

THE GOOD
Company Launches

New trade group Association of Multisite Research Corporations launches to represent 14 clinical research orgs with 400+ sites and 7,000+ staff globally
CRO, contract research, trade organization - Read more

PRESENTED BY YOU?
Get the attention of 1600+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

⬇️ More Good News ⬇️

THE GOOD
Fundraises

Retro Biosciences has lofty ambitions for a $1B fundraise and plans to push an asset into clinical trials “this year”
Protein, Alzheimer’s disease, longevity, AI - Read more

Madrona $770M Fund X and Acceleration Fund IV, AI and software focused VC with interest in life science
Venture capital, Life science investing, AI, software - Read more

TargetRx $50M Series C, developing small molecules cancer therapies
Small molecule, myeloid leukemia, lung cancer - Read more

Sen-Jam Pharmaceutical undisclosed amount strategic investment from 5 Horizons Capitals, developing meds for inflammation and metabolic disorders
Small molecule, inflammation, metabolic disorders, hangover prevention(?) - Read more

THE GOOD
Investments

AstraZeneca invests CAD 820M ($572M) in expanding Toronto operations site, creating 700 jobs to support global growth targets
Big pharma, site expansion - Read more

THE GOOD
IPOs

Chinese vaccine maker Ab&B Bio-Tech files Hong Kong IPO to fund flu and rabies vaccines development
Vaccine, influenza (flu), rabies infection - Read more

THE GOOD
Lawsuits

Purdue Pharma and Sackler family up their proposed Oxycontin/opioid crisis settlement to $7.4B
Opioid crisis, opioid epidemic - Read more

THE GOOD
Mergers & Acquisition

Exicure acquires GPCR Therapeutics' US business unit and blood cancer clinical asset burixafor (CXCR4 inhibitor)
Small molecule, myeloma, lymphoma, cancer - Read more

Joinn Biologics acquires Lonza's 183,000-square-foot biologics plant in Guangzhou, expanding its presence in China's Greater Bay Area
CDMO, contract manufacturing, site acquisition - Read more

THE GOOD
Partnerships

AbbVie, Neomorph $1.64B partnership to develop molecular glue degraders for oncology and immunology targets
Small molecule, cancer, immunology, molecular glue, drug development - Read more

Catalent, Galapagos partner on to support decentralized CAR-T therapy manufacturing for non-Hodgkin lymphoma clinical trials
Cell therapy, cancer, decentralized manufacturing, CAR-T - Read more

Genethon, Eukarÿs partner to reduce gene therapy costs through combined AAV and mRNA technologies
Gene therapy, mRNA, AAV, biomanufacturing, drug pricing - Read more

Altamira Therapeutics and an undisclosed radiopharmaceutical organization partner on testing RNA delivery platform for targeted cancer radiopharmaceutical delivery
Radiopharm, RNA, cancer, drug delivery - Read more

THE GOOD
Research

Princeton researchers develop copper-detection probe, revealing potential copper chelation treatment for specific types of lung cancer
Copper chelation treatment, lung cancer - Read more

Scientists complete final synthetic yeast chromosome in bid to build world’s first synthetic yeast genome
Synthetic genome, synthetic biology - Read more

THE GOOD
Strategic Plans

Isomorphic Labs plans to begin clinical trials of AI-designed drugs in 2025, aiming to accelerate drug discovery significantly
Drug delivery, drug design, AI - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Approvals & Labels

Stealth BioTherapeutics' elamipretide FDA decision for Barth syndrome hits delay
Tetrapeptide, Barth syndrome - Read more

THE BAD
Politics & Policy

RFK Jr. faces conflict-of-interest concerns over continued referral fees from lawsuits against Merck & Co. while seeking HHS secretary position
Vaccine, vaccine marketing, referral fees, conflict of interest - Read more

THE UGLY
Adverse Events

FDA adds black-box safety warning to Teva Pharmaceuticals’ Copaxone, citing risk of potentially severe/life-threatening allergic reaction risks
Peptide, multiple sclerosis, allergic reaction, blackbox warning - Read more

THE UGLY
Politics & Policy

Trump administration halts federal health agency communications, requiring approval for all public messages and posts
Health agency, public communications - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here